Advertisement

Journal of Bioenergetics and Biomembranes

, Volume 45, Issue 3, pp 307–315 | Cite as

Case Report: Sodium dichloroacetate (DCA) inhibition of the “Warburg Effect” in a human cancer patient: complete response in non-Hodgkin’s lymphoma after disease progression with rituximab-CHOP

  • Stephen B. StrumEmail author
  • Örn Adalsteinsson
  • Richard R. Black
  • Dmitri Segal
  • Nancy L. Peress
  • James Waldenfels
Article

Abstract

The uptake of fluorodeoxyglucose Positron Emission Tomography in the tumors of various cancer types demonstrates the key role of glucose in the proliferation of cancer. Dichloroacetate is a 2-carbon molecule having crucial biologic activity in altering the metabolic breakdown of glucose to lactic acid. Human cell line studies show that dichloroacetate switches alter the metabolomics of the cancer cell from one of glycolysis to oxidative phosphorylation, and in doing so restore mitochondrial functions that trigger apoptosis of the cancer cell. Reports of dichloroacetate in human subjects are rare. The authors contacted individuals from Internet forums who had reported outstanding anti-cancer responses to self-medication with dichloroacetate. With informed consent, complete medical records were requested to document response to dichloroacetate, emphasizing the context of monotherapy with dichloroacetate. Of ten patients agreeing to such an evaluation, only one met the criteria of having comprehensive clinic records as well as pathology, imaging and laboratory reports, along with single agent therapy with dichloroacetate. That individual is the focus of this report. In this case report of a man with documented relapse after state-of-the-art chemotherapy for non-Hodgkin’s lymphoma, a significant response to dichloroacetate is documented with a complete remission, which remains ongoing after 4 years. Dichloroacetate appears to be a novel therapy warranting further investigation in the treatment of cancer.

Keywords

Dichloroacetate DCA non-Hodgkin’s lymphoma NHL PET PET/CT Glycolysis Metabolomics Warburg 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berendzen K, Theriaque DW, Shuster J, Stacpoole PW (2006) Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion 6:126–135CrossRefGoogle Scholar
  2. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51CrossRefGoogle Scholar
  3. Bui T, Thompson CB (2006) Cancer’s sweet tooth. Cancer Cell 9:419–420CrossRefGoogle Scholar
  4. Bustamante E, Pedersen PL (1977) High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 74:3735–3739CrossRefGoogle Scholar
  5. Bustamante E, Morris HP, Pedersen PL (1981) Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 256:8699–8704Google Scholar
  6. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S et al (2008) Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68:1223–1231CrossRefGoogle Scholar
  7. Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39:267–274CrossRefGoogle Scholar
  8. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230–233CrossRefGoogle Scholar
  9. Constantin-Teodosiu D, Simpson EJ, Greenhaff PL (1999) The importance of pyruvate availability to PDC activation and anaplerosis in human skeletal muscle. Am J Physiol 276:E472–E478Google Scholar
  10. Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18:330–337CrossRefGoogle Scholar
  11. Gatenby RA, Gawlinski ET (2003) The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 63:3847–3854Google Scholar
  12. Heerdt BG, Houston MA, Augenlicht LH (2005) The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res 65:9861–9867CrossRefGoogle Scholar
  13. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M et al (2002) Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43:173–180Google Scholar
  14. Kuroda Y, Ito M, Toshima K, Takeda E, Naito E, Hwang TJ et al (1986) Treatment of chronic congenital lactic acidosis by oral administration of dichloroacetate. J Inherit Metab Dis 9:244–252CrossRefGoogle Scholar
  15. Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG (2010) Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer 102:1746–1752CrossRefGoogle Scholar
  16. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29:339–343CrossRefGoogle Scholar
  17. Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276:43407–43412CrossRefGoogle Scholar
  18. Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99:989–994CrossRefGoogle Scholar
  19. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E et al (2010) Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31ra34CrossRefGoogle Scholar
  20. Pan JG, Mak TW (2007) Metabolic targeting as an anticancer strategy: dawn of a new era? Sci STKE 2007:14Google Scholar
  21. Remillard CV, Yuan JX (2004) Activation of K+ channels: an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 286:L49–L67CrossRefGoogle Scholar
  22. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS (1997) Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 77:535–541CrossRefGoogle Scholar
  23. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM et al (2006) Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117:1519–1531CrossRefGoogle Scholar
  24. Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW et al (2008) Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 121:e1223–e1228CrossRefGoogle Scholar
  25. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC (2010) Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 120:253–260CrossRefGoogle Scholar
  26. Tong J, Xie G, He J, Li J, Pan F, Liang H (2011) Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol 2011:740564CrossRefGoogle Scholar
  27. Vander Heiden MG (2010) Targeting cell metabolism in cancer patients. Sci Transl Med 2:31ed31CrossRefGoogle Scholar
  28. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefGoogle Scholar
  29. Wang Z (2004) Roles of K+ channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch 448:274–286CrossRefGoogle Scholar
  30. Warburg O (1956a) On respiratory impairment in cancer cells. Science 124:269–270Google Scholar
  31. Warburg O (1956b) On the origin of cancer cells. Science 123:309–314CrossRefGoogle Scholar
  32. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530CrossRefGoogle Scholar
  33. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I (2008) Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109:394–402CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Stephen B. Strum
    • 1
    • 2
    • 3
    Email author
  • Örn Adalsteinsson
    • 4
  • Richard R. Black
    • 5
  • Dmitri Segal
    • 6
  • Nancy L. Peress
    • 7
  • James Waldenfels
    • 8
  1. 1.International Strategic Cancer AllianceAshlandUSA
  2. 2.American Society of Clinical OncologyAshlandUSA
  3. 3.American Urological AssociationAshlandUSA
  4. 4.International Strategic Cancer AllianceKennett SquareUSA
  5. 5.Nuclear Medicine and PET ImagingRadisphere Teleradiology GroupBeachwoodUSA
  6. 6.Valley Radiology ConsultantsPowayUSA
  7. 7.Life Extension FoundationSault Sainte MarieUSA
  8. 8.Life Extension FoundationAnnandaleUSA

Personalised recommendations